Klus Pharma is Drug Discovery in United States that focus on molecule-based therapies business. Founded in 2014. They cover business area such as developer, advanced technology platform, small molecule-base therapy, innovative biologic, biosimilar program, monoclonal antibody, antibody-drug conjugate, fusion protein, polysaccharide, physician, unmet medical need, oncology, autoimmune disease, liver disease, diabetes, cardiovascular disease, anti-infectious disease.
2014
( 10 years old in 2024 )
Molecule-based Therapies
-
8 Clarke Drive
NJ 08512
United States
Private
developeradvanced technology platformsmall molecule-base therapyinnovative biologicbiosimilar programmonoclonal antibodyantibody-drug conjugatefusion proteinpolysaccharidephysicianunmet medical needoncologyautoimmune diseaseliver diseasediabetescardiovascular diseaseanti-infectious disease
* We use standard office opening hours in near Klus Pharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Klus Pharma is Drug Discovery business from United States that founded in 2014 (10 years old in 2024), Klus Pharma business is focusing on Molecule-based Therapies.
Klus Pharma headquarter office and corporate office address is located in 8 Clarke Drive NJ 08512 United States.
Klus Pharma was founded in United States.
In 2024, Klus Pharma is currently focus on molecule-based therapies sector.
Above is snippet of Google Trends for "molecule-based therapies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Klus Pharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
